Drug Profile

Dorzagliatin/metformin - Hua Medicine

Alternative Names: HMSFDC-6857

Latest Information Update: 15 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hua Medicine
Class Antihyperglycaemics; Biguanides; Small molecules
Mechanism of Action AMP activated protein kinase stimulants; Glucokinase stimulants; Gluconeogenesis inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

15 Sep 2026 Phase-II clinical trials in Type 2 diabetes mellitus (unspecified route) before September 2026 (Hua Medicine pipeline; September 2026)
15 Sep 2026 Phase-III clinical trials in Type 2 diabetes mellitus (unspecified route) (Hua Medicine pipeline; September 2026)
20 Aug 2026 Hua Medicine plans to submit NDA with the NMPA China for Dorzagliatin/metformin for Type 2 diabetes mellitus in 2027

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com